The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...